Individual Investor
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Seeking Apha article posted on Athersys https://seekingalpha.com/article/4480602-athersys-near-term-progress-stem-cell-phase-3-trials?v=1642707251&comments=show#comment-91270460
Seeking Alpha article on VRME https://seekingalpha.com/article/4473708-verifyme-set-for-triple-digit-growth
Athersys has posted several videos in the last 30 days that affirm the power of Multistem. With multiple shots on goal, ATHX is definitely undervalued with a mere market cap of $362 million. https://www.youtube.com/channel/UCdPx7ZXYv6oLmeyjGmqXNBQ/videos
$DYAI
Deals are likely to start happening after a great deal of focus on Serum Institute of India as per article in WSJ today https://www.wsj.com/articles/covid-19-vaccines-are-becoming-important-diplomatic-currency-11613152854 as well as all four of top animal pharma players now test C1. Just a matter of time. Earlier anticipation of potential deals were premature. Human and animal pharma takes time.
At this point, it is evident that the trial did not fail on any endpoint or the company would have had to disclose. Added more shares due to improving risk profile.
We are at 9 weeks exactly today--63 days. Will be 10 weeks next Monday.
Although a small trial, impressive phase 1 trial results for DCvax-Direct for multiple solid tumor cancers:
Just want to remind everyone of the statement made by LP Nov 19, 2018 on the data release, with each stage "multi-month processes":
"The upcoming stages include finalizing the Statistical Analysis Plan, conducting the final data collection, data validation and data lock, and then unblinding and analyzing the data. Each of these are multi-month processes, and will involve tremendous work by both our team and teams of outside experts."
The chart looks great and ready to soar after a double-bottom and re-entry of PMO buy signal https://stockcharts.com/h-sc/ui
It's time you guys get some logic from the knowledgeable analyst on NWBO https://smithonstocks.com/northwest-biotherapeutics-waiting-for-top-line-data-on-dcvax-l-nwbo-1-25-buy/
We have no way of ever knowing, but my best guess is that LP gifted the options to people who have been dedicated to the process of bringing the trial to successful completion. Grandchildren would not likely have $900,000 to exercise options by Dec 1.
DSS shutting down the IP monetization business. Bye Bye Apple lawsuit.
http://filings.irdirect.net/data/771999/000149315219018140/defa14c.pdf
New SA article on Flotek https://seekingalpha.com/article/4286303-flotek-industries-drilling-value
New Seeking Alpha article https://seekingalpha.com/article/4276178-cbd-craze-secular-growth-story on CBD stocks.
New SA article on Antares https://seekingalpha.com/article/4252861-antares-pharma-business-model-stupid
Interesting article concerning Chinese stocks and the trade war https://seekingalpha.com/article/4192966-america-will-win-trade-war
New SA article discussing OESX https://seekingalpha.com/article/4157712-depressed-led-players-set-rebound
New SA artilce on Granite Construction https://seekingalpha.com/article/4136194-granite-construction-infrastructure-play. Looks like infrastructure staged a breakout today.
New Seeking Alpha article on ATRS https://seekingalpha.com/article/4124608-antares-pharma-sale
New SA article on OESX "Orion Energy Systems Down But Far From Out" https://seekingalpha.com/article/4110244-orion-energy-systems-far
tjguy,
I do not have anything specific, other than the fact that it has been roughly 6 months since TEVA responded to the CRL and the process to approval usually takes about 6 months, although TEVA has not provided exact dates.
It appears likely that the TEVA/ATRS AB rated generic EpiPen will be approved before the PDUFA date for Xyosted. The AB Epi is likely to be a catalyst before October 22.
The ATRS chart looks real good--a perfect cup-with-a-handle, above 50-day & 100-day averages, and MACD positive.
http://stockcharts.com/h-sc/ui?s=ATRS
Beckton Dickinson buys C. R. Bard for $24 billion and ATRS does not move. The market is really missing this one. Injection devices with strong IP are going to be increasingly in demand by Big Pharma. Further, pharma M & A is projected to increase in 2017 per linked article
http://bit.ly/2pdsISt ATRS is set to soar--when the market wakes up!
New SA article on OESX linked below.
http://seekingalpha.com/article/4045468-led-lighting-connected-ceiling-profit-new-paradigm
Recent SA article published on Perceptron, linked here http://seekingalpha.com/article/4054525-industrial-automation-robotics-profit-new-paradigm
New Seeking Alpha article on ATRS http://seekingalpha.com/article/4041658-antares-pharma-realistic-expectations